BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 23998577)

  • 21. Long term curative effects of sequential therapy with all-trans retinoic acid, arsenious oxide and chemotherapy on patients with acute promyelocytic leukemia.
    Pei R; Cao J; Ma J; Zhang P; Liu X; Du X; Chen D; Sha K; Chen L; Li S; Wu J; Fan Z; Lin L; Ye P; Tang S; Zhang B
    Hematology; 2012 Nov; 17(6):311-6. PubMed ID: 23168069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
    Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
    Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute promyelocytic leukemia with a STAT5b-RARα fusion transcript defined by array-CGH, FISH, and RT-PCR.
    Chen H; Pan J; Yao L; Wu L; Zhu J; Wang W; Liu C; Han Q; Du G; Cen J; Xue Y; Wu D; Sun M; Chen S
    Cancer Genet; 2012 Jun; 205(6):327-31. PubMed ID: 22749039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
    Diverio D; Rossi V; Avvisati G; De Santis S; Pistilli A; Pane F; Saglio G; Martinelli G; Petti MC; Santoro A; Pelicci PG; Mandelli F; Biondi A; Lo Coco F
    Blood; 1998 Aug; 92(3):784-9. PubMed ID: 9680345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcription therapy for acute promyelocytic leukaemia.
    Douer D
    Expert Opin Investig Drugs; 2000 Feb; 9(2):329-46. PubMed ID: 11060680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.
    Shen ZX; Shi ZZ; Fang J; Gu BW; Li JM; Zhu YM; Shi JY; Zheng PZ; Yan H; Liu YF; Chen Y; Shen Y; Wu W; Tang W; Waxman S; De Thé H; Wang ZY; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5328-35. PubMed ID: 15044693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia.
    Ohnishi K
    Int J Clin Oncol; 2007 Oct; 12(5):313-7. PubMed ID: 17929112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cleavage product deltaPML-RARalpha contributes to all-trans retinoic acid-mediated differentiation in acute promyelocytic leukemia cells.
    Jing Y; Xia L; Lu M; Waxman S
    Oncogene; 2003 Jun; 22(26):4083-91. PubMed ID: 12821942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disappearance of PML/RAR alpha acute promyelocytic leukemia-associated transcript during consolidation chemotherapy.
    Martinelli G; Ottaviani E; Testoni N; Visani G; Diverio D; D'Elia G; Mandelli F; Tura S
    Haematologica; 1998 Nov; 83(11):985-8. PubMed ID: 9864917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia.
    Li K; Wang F; Yang ZN; Cui B; Li PP; Li ZY; Hu ZW; Zhu HH
    Theranostics; 2020; 10(22):10326-10340. PubMed ID: 32929351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in therapies for acute promyelocytic leukemia.
    Kamimura T; Miyamoto T; Harada M; Akashi K
    Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
    Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
    Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. The Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho).
    Fukutani H; Naoe T; Ohno R; Yoshida H; Miyawaki S; Shimazaki C; Miyake T; Nakayama Y; Kobayashi H; Goto S
    Leukemia; 1995 Sep; 9(9):1478-82. PubMed ID: 7658715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
    Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
    Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure.
    Gallagher RE; Schachter-Tokarz EL; Zhou DC; Ding W; Kim SH; Sankoorikal BJ; Bi W; Livak KJ; Slack JL; Willman CL
    Leukemia; 2006 Apr; 20(4):556-62. PubMed ID: 16437139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia.
    Albano F; Zagaria A; Anelli L; Coccaro N; Tota G; Brunetti C; Minervini CF; Impera L; Minervini A; Cellamare A; Orsini P; Cumbo C; Casieri P; Specchia G
    Oncotarget; 2015 May; 6(15):13269-77. PubMed ID: 25944686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical observation of the short-term efficacy of the treatment with combination of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL)].
    Liu YF; Shen ZX; Chen X; Wang AH; Cao Q; Zhu YM; Chen SJ; Chen Z; Wang ZY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):25-7. PubMed ID: 12679006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ; Chen LJ; Zhou GB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.